HeartSciences Inc. HSCS 深 沪
等待开盘 05-21 09:30:00 美东时间
1.93
+0.050
+2.66%
华盛通- 最 高1.9399
- 今 开1.86
- 成交量 2.00万股
- 最 低 1.84
- 昨 收 1.88
- 总市值 614.65万
- 52周最高 6.47
- 市盈率 静 --
- 换手率 0.63%
- 52周最低 1.77
- 委 比 64.47%
- 总股本 318.47万
- 历史最高 600.00
- 量 比 1.33
- 振 幅 5.31%
- 历史最低 1.77
- 每 手 1
- 风险率 0.64%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多HeartSciences Stockholders Approve Director Election and Equity Plan
The latest update is out from Heart Test Laboratories, Inc. ( ($HSCS) ). On Apr...
05-07 07:28
HeartSciences Signs Commercial Agreement With St. Vincent Health, Critical Access Hospital Serving Lake County, Colorado, To Deploy MyoVista Insights Platform
HeartSciences Inc. (NASDAQ:HSCS, HSCSW))) ("HeartSciences" or the "Company"), a healthcare information technology ("HIT") company focused on advancing electrocardiography ("ECG" or "EKG") through the integration of
05-05 21:04
HeartSciences COO and Longtime Board Member Passes Away
The latest announcement is out from Heart Test Laboratories, Inc. ( ($HSCS) ). ...
04-04 05:53
HeartSciences’ MyoVista Insights™ Receives Epic Toolbox Designation for ECG Management System Category
HeartSciences Inc. announced that its MyoVista Insights platform has been designated as an Epic Toolbox solution for the ECG Management System category. The cloud-native platform enhances workflow efficiency and integrates with hospital systems, including Epic, through HL7v2, SSO, and SMART on FHIR. This integration allows clinicians to access the platform seamlessly within their existing workflows. The designation, achieved after meeting Epic’s ...
03-25 12:30
美股大行评级 | 潜在涨幅499.25%！Cabaletta Bio获Guggenheim升目标价至16美元，维持"买入"评级
今日重点评级关注：Guggenheim：维持Cabaletta Bio"买入"评级，目标价从15美元升至16美元；HC Wainwright & Co.：维持Palvella Therapeutics"买入"评级，目标价从255美元升至270美元
03-25 10:31
Pfizer To Rally More Than 34%? Here Are 10 Top Analyst Forecasts For Tuesday
Analysts change ratings & price targets for HSCS, ONDS, STRO, PFE, HST, CABA, INSM, PVH. See full list & how others rate each stock.
03-24 21:40
Ascendiant Capital Maintains Buy on HeartSciences, Lowers Price Target to $8
Ascendiant Capital analyst Lucas Ward maintains HeartSciences (NASDAQ:HSCS) with a Buy and lowers the price target from $9.2 to $8.
03-24 18:06
HeartSciences to Present at Investor Summit Group Virtual Conference and Host Virtual One on One Investor Meetings
HeartSciences Inc., a healthcare IT company advancing ECG technology with AI, will present at the Investor Summit Group Virtual Conference on March 25, 2026. The company's CEO, Andrew Simpson, will discuss its business strategy, recent achievements, and growth plans. HeartSciences also plans one-on-one investor meetings on March 26. The event aims to enhance the company's market visibility and investor engagement. For more details, visit their we...
03-24 15:18
Heart Test Laboratories Q3 EPS $(0.63) Beats $(0.86) Estimate
Heart Test Laboratories (NASDAQ:HSCS) reported quarterly losses of $(0.63) per share which beat the analyst consensus estimate of $(0.86) by 26.74 percent. This is a 75.49 percent increase over losses of $(2.57) per
03-17 04:26
